Qlife Holding AB (publ)

Stockholm Stock Exchange QLIFE.ST

Qlife Holding AB (publ) EBIT for the year ending December 31, 2023: USD -15.52 M

Qlife Holding AB (publ) EBIT is USD -15.52 M for the year ending December 31, 2023, a -69.10% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Qlife Holding AB (publ) EBIT for the year ending December 31, 2022 was USD -9.18 M, a -89.74% change year over year.
Qlife Holding AB (publ) EBIT for the year ending December 31, 2021 was USD -4.84 M, a -27.17% change year over year.
Qlife Holding AB (publ) EBIT for the year ending December 31, 2020 was USD -3.80 M, a -600.20% change year over year.
Qlife Holding AB (publ) EBIT for the year ending December 31, 2019 was USD -543.31 K.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Stockholm Stock Exchange: QLIFE.ST

Qlife Holding AB (publ)

CEO	Mr. Thomas Warthoe
IPO Date	March 2, 2020
Location	Sweden
Headquarters	Redaregatan 48
Employees	24
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents. The company offers Egoo.Health Platform, an integrated platform with a measuring instrument with disposable capsules and software, where each capsule contains a test for a specific biomarker or virus. Its biomarkers include C-reactive protein home-testing capsule, PHE/Phenylalanine for PKU patients, and Sars-CoV-2/Influenza multiplex for virus/bacteria tests. The company was incorporated in 2019 and is based in Helsingborg, Sweden.

Key trends

Past 5 years